.jpg?format=webp&width=780)
A new study investigated the potential of neoadjuvant immunotherapy for locally advanced thymic malignancies. Over 12 patients with thymic tumors underwent surgical resection after receiving immune checkpoint inhibitors (ICI) as part of their treatment. Thymic carcinomas responded well to ICI-based therapy, with a 66.7% complete resection rate and a median progression-free survival of 17 months. These findings highlight the promise of neoadjuvant ICI-based therapy in advanced thymic carcinomas and suggest the need for future clinical trials in this area.
Like
Save
Share